Publications by authors named "Kentaro Enjo"

Claim this Profile
E
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study.
Satoshi Fukasawa, Hiroyoshi Suzuki, Kazushiro Kawaguchi, Hidehisa Noguchi, Kentaro Enjo

Jpn J Clin Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis.
Joerg Mahlich, Akiko Tsubota, Keiichiro Imanaka, Kentaro Enjo

Curr Med Res Opin· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).
Aya Kikuchi, Takashi Furutani, Hidenori Azami, Kazushi Watanabe, Tatsuya Niimi, Kentaro Enjo

Invest New Drugs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
Kazushi Watanabe, Akio Kakefuda, Minoru Yasuda, Kentaro Enjo, Aya Kikuchi

Bioorg Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
Osamu Ishimoto, Chikashi Kawahara, Kentaro Enjo, Masuo Obinata, Toshihiro Nukiwa

Cancer Res· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis